文献速递肝胆胰外科围术期管理与 ERAS

Oddi括约肌肉毒毒素注射预防远端胰腺切除术后胰瘘

Sphincter of Oddi botulinum toxin injection to prevent pancreatic fistula after distal pancreatectomy.
PubMed 文献 · Surgery · 2016-11-16

本研究为研究者发起的I/II期探索性临床试验,评估术前内镜下Oddi括约肌注射肉毒毒素(100单位Botox)预防远端胰腺切除术后胰瘘的可行性与安全性。29例患者中24例行远端胰腺切除,肉毒毒素组无临床相关胰瘘(B/C级),而病例对照匹配组B/C级胰瘘发生率为33%(P < .004)。

要点

  • 术前Oddi括约肌肉毒毒素注射可行且安全,仅1例出现短暂无症状淀粉酶/脂肪酶升高。
  • 肉毒毒素组无B/C级临床相关胰瘘,对照组为33%(P < .004)。
  • 肉毒毒素组29%出现A级生化瘘,无需干预。

核心结论

  • 术前Oddi括约肌肉毒毒素注射是降低远端胰腺切除术后临床相关胰瘘发生率的新颖且安全的方法。
  • 本试验结果提示其预防临床相关胰瘘有效,目前正在德国联邦政府资助的多中心随机对照PREBOT试验中验证。

研究设计与样本

  • 研究者发起的、前瞻性临床I/II期试验,采用探索性研究设计(德国临床试验注册号:DRKS00007885)。
  • 纳入术前接受内镜下Oddi括约肌肉毒毒素注射(100单位Botox)的患者。
  • 肉毒毒素组与未注射肉毒毒素的远端胰腺切除术患者按1:1比例进行病例对照匹配。
  • 2015年2月至2016年2月期间共纳入29例患者。

主要发现

  • 所有患者均在术前中位6天(范围0-10天)成功完成Oddi括约肌肉毒毒素注射。
  • 1例患者注射后出现无症状、自限性(48小时)血清淀粉酶和脂肪酶升高。
  • 29例中24例行远端胰腺切除术,5例不可切除。
  • 肉毒毒素组7例(29%)在术后第3天引流液淀粉酶升高(国际胰腺外科研究组定义的A级胰瘘),无症状且无需再干预。
  • 肉毒毒素组未观察到临床相关胰瘘(B/C级),而病例对照组B/C级胰瘘发生率为33%(P < .004)。

临床怎么用

  • 对于拟行远端胰腺切除术的患者,可考虑术前内镜下Oddi括约肌注射肉毒毒素(100单位Botox)以预防临床相关胰瘘。
  • 该操作安全可行,术前中位6天实施,仅见短暂无症状胰酶升高。

局限性

  • 本研究为探索性I/II期试验,样本量较小(29例),需多中心随机对照试验进一步验证。
  • 采用病例对照匹配设计,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative pancreatic fistula represents the most important complication after distal pancreatectomy. The aim of this study was to evaluate the use of a preoperative endoscopic injection of botulinum toxin into the sphincter of Oddi to prevent postoperative pancreatic fistula (German Clinical Trials Register number: DRKS00007885). METHODS: This was an investigator-initiated, prospective clinical phase I/II trial with an exploratory study design. We included patients who underwent preoperative endoscopic sphincter botulinum toxin injection (100 units of Botox). End points were the feasibility, safety, and postoperative outcomes, including postoperative pancreatic fistula within 30 days after distal pancreatectomy. Botulinum toxin patients were compared with a control collective of patients undergoing distal pancreatectomy without botulinum toxin injection by case-control matching in a 1:1 ratio. RESULTS: Between February 2015 and February 2016, 29 patients were included. All patients underwent successful sphincter of Oddi botulinum toxin injection within a median of 6 (range 0-10) days before operation. One patient had an asymptomatic, self-limiting (48 hours) increase in serum amylase and lipase after injection. Distal pancreatectomy was performed in 24/29 patients; 5 patients were not resectable. Of the patients receiving botulinum toxin, 7 (29%) had increased amylase levels in drainage fluid on postoperative day 3 (the International Study Group of Pancreatic Surgery definition of postoperative pancreatic fistula grade A) without symptoms or need for reintervention. Importantly, no clinically relevant fistulas (International Study Group of Pancreatic Surgery grades B/C) were observed in botulinum toxin patients compared to 33% postoperative pancreatic fistula grade B/C in case-control patients (P < .004). CONCLUSION: Preoperative sphincter of Oddi botulinum toxin injection is a novel and safe approach to decrease the incidence of clinically relevant postoperative pancreatic fistula after distal pancreatectomy. The results of the present trial suggest its efficacy in the prevention of clinically relevant postoperative pancreatic fistula and are validated currently in the German Federal Government-sponsored, multicenter, randomized controlled PREBOT trial.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Hackert T, Klaiber U, Hinz U, et al. Sphincter of Oddi botulinum toxin injection to prevent pancreatic fistula after distal pancreatectomy. Surgery. 2016. PMID: 27865590. doi:10.1016/j.surg.2016.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。